Craft
  • Home
  •  / Rubius Therapeutics
Rubius Therapeutics

Rubius Therapeutics

Market Capitalization

$20 M

2022-11-21

Rubius Therapeutics Summary

Company summary

Overview
Rubius Therapeutics is developing Red-Cell Therapeutics™ (RCTs™) as a new class of medicines to address a wide array of indications, with leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
Type
Public
Status
Active
Founded
2013
HQ
Cambridge, MA, US | view all locations
Website
http://www.rubiustx.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Pablo J. Cagnoni

    Pablo J. Cagnoni, President, Chief Executive Officer, Director

    • Dannielle Appelhans

      Dannielle Appelhans, Chief Operating Officer

      • Spencer Fisk

        Spencer Fisk, Chief Technical Operations Officer

        • Maiken Keson-Brookes

          Maiken Keson-Brookes, Chief Legal Officer and Corporate Secretary

          LocationsView all

          2 locations detected

          • Cambridge, MA HQ

            United States

            399 Binney St #300

          • Smithfield, RI

            United States

            100 Technology Way

          Rubius Therapeutics Financials

          Summary financials

          Net income (Q3, 2022)
          ($62.9M)
          Cash (Q3, 2022)
          $103.9M
          EBIT (Q3, 2022)
          ($61.6M)
          Enterprise value
          $26.8M

          Footer menu